Maggie C. Louie, Ph.D.
Affiliations: | 2004 | University of California, Davis, Davis, CA |
Area:
Molecular Biology, Cell Biology, BiochemistryGoogle:
"Maggie Louie"Parents
Sign in to add mentor| Hongwu Chen | grad student | 2004 | UC Davis | |
| (The role of coactivator ACTR in the control of transcription and cell proliferation.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Magbanua MJM, Brown-Swigart L, Hirst G, et al. (2020) Abstract P5-01-04: Personalized monitoring of circulating tumor DNA during neoadjuvant therapy in high-risk early stage breast cancer reflects response and risk of metastatic recurrence Cancer Research. 80 |
| Ginn E, Baek J, Zou H, et al. (2019) Enantiomer of the novel flexible heteroarotinoid, SL-1-09, blocks cell cycle progression in breast cancer cells. European Journal of Pharmacology. 172634 |
| Bloomfield M, Louie MC. (2019) Chronic cadmium exposure decreases the dependency of MCF7 breast cancer cells on ERα. Scientific Reports. 9: 12135 |
| Coombes C, Page K, Salari R, et al. (2019) Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Zou H, Sevigny MB, Liu S, et al. (2019) Novel flexible heteroarotinoid, SL-1-39, inhibits HER2-positive breast cancer cell proliferation by promoting lysosomal degradation of HER2. Cancer Letters. 443: 157-166 |
| Magbanua M, Brown-Swigart L, Hirst G, et al. (2019) Abstract PD2-01: Personalized serial circulating tumor DNA (ctDNA) analysis in high-risk early stage breast cancer patients to monitor and predict response to neoadjuvant therapy and outcome in the I-SPY 2 TRIAL Cancer Research. 79 |
| Coombes R, Armstrong AC, Ahmed S, et al. (2019) Abstract P4-01-02: Early detection of residual breast cancer through a robust, scalable and personalized analysis of circulating tumour DNA (ctDNA) antedates overt metastatic recurrence Cancer Research. 79 |
| Louie MC, Sevigny MB. (2017) Steroid hormone receptors as prognostic markers in breast cancer. American Journal of Cancer Research. 7: 1617-1636 |
| Fallatah M, Liu S, Sevigny MB, et al. (2017) Novel flexible heteroarotinoid, SL-1-18, promotes ERα degradation to inhibit breast cancer cell growth. Cancer Letters |
| Zou H, Ginn E, Francis SM, et al. (2017) Abstract 2090: Targeting estrogen receptor negative breast cancer cells using diarylthiourea analogs of SHetA2 Cancer Research. 77: 2090-2090 |